Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FKBP1A | P62942 | 7/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3742096 | 0.90 | FKBP1A (0.54) | FKBP1AKDM4EALDH1A1HPGDSMN1; SMN2 | |
| SCHEMBL3731038 | 0.86 | LMNA (0.47) | FKBP1AALDH1A1SMN1; SMN2 | |
| SCHEMBL3747517 | 0.86 | LMNA (0.47) | FKBP1AALDH1A1SMN1; SMN2 | |
| SCHEMBL3736446 | 0.85 | ACE (0.49) | L3MBTL1 | |
| SCHEMBL13041397 | 0.84 | FKBP1A (0.56) | FKBP1AKDM4EALDH1A1HPGDSMN1; SMN2 | |
| SCHEMBL8626274 | 0.81 | FKBP1A (0.56) | FKBP1AKDM4EALDH1A1HPGDSMN1; SMN2 | |
| SCHEMBL3745290 | 0.81 | ACE (0.53) | KDM4EHSD17B10L3MBTL1 | |
| SCHEMBL6883997 | 0.80 | FKBP1A (0.53) | FKBP1AKDM4EALDH1A1HPGDSMN1; SMN2 | |
| SCHEMBL5496855 | 0.80 | FKBP1A (0.53) | FKBP1AKDM4EALDH1A1HPGDSMN1; SMN2 | |
| SCHEMBL5496862 | 0.80 | FKBP1A (0.53) | FKBP1AKDM4EALDH1A1HPGDSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100280034-A1 | Modulation of pathogenicity | QUONOVA, LLC | 2010-11-04 | — | — | US | disclosed |
| US-7338969-B2 | Modulation of pathogenicity | QUONOVA, LLC (US) | 2008-03-04 | — | — | US | disclosed |
| US-20070208012-A1 | Modulation of Pathogenicity | QUONOVA, LLC | 2007-09-06 | — | — | US | disclosed |
| US-20070203128-A1 | Modulation of Pathogenicity | QUONOVA, LLC | 2007-08-30 | — | — | US | disclosed |
| US-20070196340-A1 | Modulation of Pathogenicity | QUONOVA, LLC | 2007-08-23 | — | — | US | disclosed |
| US-20070197492-A1 | Modulation of Pathogenicity | QUONOVA, LLC | 2007-08-23 | — | — | US | disclosed |
| US-20070184014-A1 | Modulation of Pathogenicity | QUONOVA, LLC | 2007-08-09 | — | — | US | disclosed |
| US-20070093534-A1 | Modulation of Pathogenicity | QUONOVA, LLC | 2007-04-26 | — | — | US | disclosed |
| EP-1622890-A2 | BLOCKERS OF THE QUORUM SENSING SYSTEM OF GRAM-NEGATIVE BACTERIA | 4SC AG (DE) | 2006-02-08 | — | — | EP | disclosed |
| US-20040235914-A1 | Modulation of pathogenicity | 4 SC AG (DE) | 2004-11-25 | — | — | US | disclosed |
| WO-2004099175-A2 | BLOCKERS OF THE QUORUM SENSING SYSTEM OF GRAM-NEGATIVE BACTERIA | 4SC AG (DE) | 2004-11-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070197492-A1 | Modulation of Pathogenicity | ANTXR2, Q6ZSR9, PGLS | FKBP1A 2387/4885KDM4E 2482/4885ALDH1A1 4721/4885 |
| US-20070203128-A1 | Modulation of Pathogenicity | ANTXR2, Q6ZSR9, PGLS | FKBP1A 2387/4885KDM4E 2482/4885ALDH1A1 4721/4885 |
| US-20070093534-A1 | Modulation of Pathogenicity | NR1H4, NR1I3, NR1H2 | FKBP1A 3800/4885KDM4E 3854/4885ALDH1A1 3931/4885 |
| US-20040235914-A1 | Modulation of pathogenicity | Q6ZSR9, CCL11, CFH | FKBP1A 4719/4885KDM4E 3241/4885ALDH1A1 4526/4885 |
| US-20070208012-A1 | Modulation of Pathogenicity | ANTXR2, Q6ZSR9, PGLS | FKBP1A 2387/4885KDM4E 2482/4885ALDH1A1 4721/4885 |
| US-20100280034-A1 | Modulation of pathogenicity | NR1H4, NR1I3, NR1H2 | FKBP1A 3800/4885KDM4E 3854/4885ALDH1A1 3931/4885 |
| US-20070184014-A1 | Modulation of Pathogenicity | ANTXR2, Q6ZSR9, PGLS | FKBP1A 2387/4885KDM4E 2482/4885ALDH1A1 4721/4885 |
| US-20070196340-A1 | Modulation of Pathogenicity | NR1H4, NR1I3, NR1H2 | FKBP1A 3800/4885KDM4E 3854/4885ALDH1A1 3931/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.